DaVita Inc. (DVA)
NYSE:DVA
Want to see DVA full AI Analyst Report?
DVA Stock Chart & Stats
$147.91
$0.74(0.48%)
At close: 4:00 PM EST
$147.91
$0.74(0.48%)
Day’s Range― - ―
52-Week Range$101.00 - $202.69
Previous CloseN/A
Volume85.32K
Average Volume (3M)914.80K
Market Cap
$12.74B
Enterprise Value$25.24B
Total Cash (Recent Filing)$748.71M
Total Debt (Recent Filing)$13.22B
Price to Earnings (P/E)13.1
Beta0.50
Next Earnings
Aug 05, 2026EPS Estimate
3.81Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)10.15
Shares Outstanding64,200,000
10 Day Avg. Volume1,042,574
30 Day Avg. Volume914,796
Financial Highlights & Ratios
PEG Ratio-1.11
Price to Book (P/B)-15.02
Price to Sales (P/S)0.72
P/FCF Ratio7.46
Enterprise Value/Market Cap1.98
Enterprise Value/Revenue1.82
Enterprise Value/Gross Profit5.87
Enterprise Value/Ebitda9.35
Forecast
1Y Price Target
$211.00Price Target Upside42.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)14.7
Revenue Forecast (FY)$14.09B
Bulls Say, Bears Say
Bulls Say
Home Health Services ProfitabilityAnalyst highlights that strategic investment in a profitable, scaled home health services business should contribute positively to earnings from the outset and strengthen consolidated results.
Missed-treatment ReductionAnalyst notes that targeted follow-up for patients who miss dialysis sessions can reduce missed treatments concentrated in a small group, preserving treatment volumes and preventing habit formation.
Outcomes-driven Volume GrowthManagement expects a return to sustainable non-acquired treatment volume growth by improving patient outcomes and reducing mortality, a historical driver of volume expansion.
Bears Say
Dialysis Technology Trial LimitationsAnalyst reports that new hemodiafiltration machines currently being trialed are not expected to meaningfully increase treatment volumes, limiting growth potential from the technology.
Health Policy HeadwindsHealth policy headwinds related to the ACA are expected to weigh on financial results and could pressure revenue and margins.
DaVita News
DVA FAQ
What was DaVita Inc.’s price range in the past 12 months?
DaVita Inc. lowest stock price was $101.00 and its highest was $202.69 in the past 12 months.
What is DaVita Inc.’s market cap?
DaVita Inc.’s market cap is $12.74B.
When is DaVita Inc.’s upcoming earnings report date?
DaVita Inc.’s upcoming earnings report date is Aug 05, 2026 which is in 73 days.
How were DaVita Inc.’s earnings last quarter?
DaVita Inc. released its earnings results on May 05, 2026. The company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.33 by $0.54.
Is DaVita Inc. overvalued?
According to Wall Street analysts DaVita Inc.’s price is currently Undervalued.
Does DaVita Inc. pay dividends?
DaVita Inc. does not currently pay dividends.
What is DaVita Inc.’s EPS estimate?
DaVita Inc.’s EPS estimate is 3.81.
How many shares outstanding does DaVita Inc. have?
DaVita Inc. has 64,200,000 shares outstanding.
What happened to DaVita Inc.’s price movement after its last earnings report?
DaVita Inc. reported an EPS of $2.87 in its last earnings report, beating expectations of $2.33. Following the earnings report the stock price went up 23.459%.
Which hedge fund is a major shareholder of DaVita Inc.?
Currently, no hedge funds are holding shares in DVA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
DaVita Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$211.00 (42.65% Upside)
$211.00 (42.65% Upside)
Blogger Sentiment
Bullish
DVA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.4%
Last 30 Days ▲ 16.2%
Last 30 Days ▲ 16.2%
News Sentiment
Bullish
Bullish news 79%
Bearish news 33%
Bearish news 33%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.31%
12-Months-Change
Fundamentals
Return on Equity
-133.12%
Trailing 12-Months
Asset Growth
2.22%
Trailing 12-Months
Company Description
DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company provides disease management services to 16,000 patients in risk-based integrated care arrangements and 7,000 patients in other integrated care arrangements; vascular access services; clinical research programs; physician services; and comprehensive kidney care services. As of December 31, 2021, it provided dialysis and administrative services in the United States through a network of 2,815 outpatient dialysis centers serving approximately 203,100 patients; and operated 339 outpatient dialysis centers located in 10 countries outside of the United States serving approximately 39,900 patients. Further, the company provides acute inpatient dialysis services in approximately 850 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
DVA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflected a generally positive tone: the company beat Q1 expectations, raised and narrowed full-year adjusted operating income and EPS guidance, demonstrated productivity-led cost improvements, and highlighted strong IKC clinical and savings performance. Material investments in technology and AI were emphasized as strategic drivers of future clinical and operational outperformance. Offsetting items included near-term pressure from higher G&A (driven by technology spend), an IKC operating loss, modest treatment declines versus prior year, ACA enrollment/mix uncertainty that could pressure revenue per treatment later in the year, and unchanged free cash flow guidance. On balance, the positive beats, guidance raise, and structural investments outweighed the near-term headwinds.View all DVA earnings summariesDVA Revenue Breakdown
85.99% U.S. dialysis
14.01% Ancillary services
DVA Stock 12 Month Forecast
Average Price Target
$211.00
▲(42.65% Upside)
Technical Analysis
Fresenius Medical Care
―
HCA Healthcare
―
Encompass Health
―
Tenet Healthcare
―
The Ensign Group
―
Ownership Overview
47.20% Insiders
10.61% Mutual Funds
4.39% Other Institutional Investors
21.04% Public Companies and
Individual Investors